Trial Outcomes & Findings for A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children (NCT NCT02435069)
NCT ID: NCT02435069
Last Updated: 2019-08-28
Results Overview
Fecal soiling was defined as non-toilet elimination, which was tracked and documented by the parent/child as direct event recording and tallied as the number of pairs of underwear/protective undergarments soiled with stool per day. The purpose of this outcome measure was to document the number of individuals who gained continence on NS and USP glycerin. Descriptive statistics was limited to percentage of total participants who achieved continence on each flushing regimen. Data was calculated on the last data point in the final phase for both the NS and USP glycerin flush.
COMPLETED
PHASE4
5 participants
Data collection started following consent and procedural training and was collected daily from day 1 for the duration of the study, an average of 135 days.
2019-08-28
Participant Flow
Participants recruited from subspecialty clinics at Nemours Children's Clinic in Jacksonville, Florida between February 2016 and January of 2017
9 assessed for eligibility, 4 excluded (3 did not meet inclusion criteria and 1 surgery date significantly delayed), 5 consented and randomized to treatment sequence in dosing phase (3 started on saline followed by USP Glycerin, 2 started on USP glycerin followed by saline).
Participant milestones
| Measure |
No Intervention: Pre-operative Baseline Phase
Baseline data including frequency and severity of fecal soiling and frequency and severity of abdominal pain were collected for a minimum of 2 weeks prior to surgical construction of the ACE stoma. Baseline stool calprotectin and serum electrolytes were collected in the baseline phase prior to initiation of the preoperative bowel prep. Pre-operative data served as the control.
|
Post-Operative Dose Response: NS Then USP Glycerin
Subjects randomized to treatment sequence. Arm evaluated dose-response relationship and was used to identify the minimum dosing volume and frequency of ACE administration for NS and USP glycerin necessary to meet outcome criteria. NS started at 10mL/kg administered every other day. Dose titrated to achieve continence so as not to exceed 500 mL NS daily for a child under five years of age, 1000 mL NS daily for a child over 5 years of age. Participant continued on effective dose for 2 weeks to insure treatment stability and effectiveness. If the maximum dose did not result in continence, if the dose necessary to minimize side effects resulted in episodes of fecal soiling, or if there were side effects greater than WBFPRS level 4 at the lowest dose of administration, the child was trialed on the alternate therapy and then dropped from the study.
|
Post-Operative Dose Response: USP Glycerin Then NS
Subjects randomized to treatment sequence. Arm evaluated dose-response relationship and was used to identify the minimum dosing volume and frequency of ACE administration for USP glycerin and necessary to meet outcome criteria. Glycerin started at 20 mL administered every other day. Dose titrated to achieve continence so as not to exceed 50 mL daily. Participant continued on effective dose for 2 weeks to insure treatment stability and effectiveness. If the maximum dose did not result in continence, if the dose necessary to minimize side effects resulted in episodes of fecal soiling, or if there were side effects greater than WBFPRS level 4 at the lowest dose of administration, the child was trialed on the alternate therapy and then dropped from the study.
|
Effectiveness Phase: NS Then USP Glycerin
To prevent statistical bias from subject loss due to treatment failure, each child who successfully completed the dosing phase was randomized to a second treatment sequence once they have achieved continence on optimal dosing with minimal side effects. This arm evaluated the long term effectiveness of NS at optimal dose and administration frequency for 4 weeks and served as comparison between flush solutions. The study concluded with the child being placed back on 2 weeks of the initial flush in the randomized sequence.
|
Effectiveness Phase: USP Glycerin Then NS
To prevent statistical bias from subject loss due to treatment failure, each child who successfully completed the dosing phase was randomized to a second treatment sequence once they have achieved continence on optimal dosing with minimal side effects. This arm evaluated the long term effectiveness of USP glycerin at optimal dose and administration frequency for 4 weeks and served as comparison between flush solutions. The study concluded with the child being placed back on 2 weeks of the initial flush in the randomized sequence.
|
|---|---|---|---|---|---|
|
Preoperative Baseline Phase
STARTED
|
5
|
0
|
0
|
0
|
0
|
|
Preoperative Baseline Phase
COMPLETED
|
5
|
0
|
0
|
0
|
0
|
|
Preoperative Baseline Phase
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
|
Dose Response - First Intervention
STARTED
|
0
|
3
|
2
|
0
|
0
|
|
Dose Response - First Intervention
COMPLETED
|
0
|
2
|
1
|
0
|
0
|
|
Dose Response - First Intervention
NOT COMPLETED
|
0
|
1
|
1
|
0
|
0
|
|
Effectiveness - Second Intervention
STARTED
|
0
|
0
|
0
|
1
|
1
|
|
Effectiveness - Second Intervention
COMPLETED
|
0
|
0
|
0
|
1
|
0
|
|
Effectiveness - Second Intervention
NOT COMPLETED
|
0
|
0
|
0
|
0
|
1
|
Reasons for withdrawal
| Measure |
No Intervention: Pre-operative Baseline Phase
Baseline data including frequency and severity of fecal soiling and frequency and severity of abdominal pain were collected for a minimum of 2 weeks prior to surgical construction of the ACE stoma. Baseline stool calprotectin and serum electrolytes were collected in the baseline phase prior to initiation of the preoperative bowel prep. Pre-operative data served as the control.
|
Post-Operative Dose Response: NS Then USP Glycerin
Subjects randomized to treatment sequence. Arm evaluated dose-response relationship and was used to identify the minimum dosing volume and frequency of ACE administration for NS and USP glycerin necessary to meet outcome criteria. NS started at 10mL/kg administered every other day. Dose titrated to achieve continence so as not to exceed 500 mL NS daily for a child under five years of age, 1000 mL NS daily for a child over 5 years of age. Participant continued on effective dose for 2 weeks to insure treatment stability and effectiveness. If the maximum dose did not result in continence, if the dose necessary to minimize side effects resulted in episodes of fecal soiling, or if there were side effects greater than WBFPRS level 4 at the lowest dose of administration, the child was trialed on the alternate therapy and then dropped from the study.
|
Post-Operative Dose Response: USP Glycerin Then NS
Subjects randomized to treatment sequence. Arm evaluated dose-response relationship and was used to identify the minimum dosing volume and frequency of ACE administration for USP glycerin and necessary to meet outcome criteria. Glycerin started at 20 mL administered every other day. Dose titrated to achieve continence so as not to exceed 50 mL daily. Participant continued on effective dose for 2 weeks to insure treatment stability and effectiveness. If the maximum dose did not result in continence, if the dose necessary to minimize side effects resulted in episodes of fecal soiling, or if there were side effects greater than WBFPRS level 4 at the lowest dose of administration, the child was trialed on the alternate therapy and then dropped from the study.
|
Effectiveness Phase: NS Then USP Glycerin
To prevent statistical bias from subject loss due to treatment failure, each child who successfully completed the dosing phase was randomized to a second treatment sequence once they have achieved continence on optimal dosing with minimal side effects. This arm evaluated the long term effectiveness of NS at optimal dose and administration frequency for 4 weeks and served as comparison between flush solutions. The study concluded with the child being placed back on 2 weeks of the initial flush in the randomized sequence.
|
Effectiveness Phase: USP Glycerin Then NS
To prevent statistical bias from subject loss due to treatment failure, each child who successfully completed the dosing phase was randomized to a second treatment sequence once they have achieved continence on optimal dosing with minimal side effects. This arm evaluated the long term effectiveness of USP glycerin at optimal dose and administration frequency for 4 weeks and served as comparison between flush solutions. The study concluded with the child being placed back on 2 weeks of the initial flush in the randomized sequence.
|
|---|---|---|---|---|---|
|
Dose Response - First Intervention
Adverse Event
|
0
|
1
|
1
|
0
|
0
|
|
Effectiveness - Second Intervention
Lack of Efficacy
|
0
|
0
|
0
|
0
|
1
|
Baseline Characteristics
A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children
Baseline characteristics by cohort
| Measure |
No Intervention: Pre-operative Baseline Phase
n=5 Participants
Baseline data including frequency and severity of fecal soiling and frequency and severity of abdominal pain were collected for a minimum of 2 weeks prior to surgical construction of the ACE stoma. Baseline stool calprotectin and serum electrolytes were collected in the baseline phase prior to initiation of the preoperative bowel prep. Pre-operative data served as the control.
|
|---|---|
|
Age, Categorical
<=18 years
|
5 Participants
n=99 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=99 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
|
Age, Continuous
|
66.6 months
STANDARD_DEVIATION 29.3309 • n=99 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
5 Participants
n=99 Participants
|
|
Race/Ethnicity, Customized
Caucasian
|
2 participants
n=99 Participants
|
|
Race/Ethnicity, Customized
Asian
|
1 participants
n=99 Participants
|
|
Race/Ethnicity, Customized
Hispanic
|
1 participants
n=99 Participants
|
|
Race/Ethnicity, Customized
African-American
|
1 participants
n=99 Participants
|
|
Region of Enrollment
United States
|
5 participants
n=99 Participants
|
|
Cause of Neurogenic bowel
myelomeningocele
|
4 participants
n=99 Participants
|
|
Cause of Neurogenic bowel
Spinal Cord Trauma - MVA
|
1 participants
n=99 Participants
|
|
Patulent anus
|
5 participants
n=99 Participants
|
|
Ambulatory
Ambulatory
|
4 participants
n=99 Participants
|
|
Ambulatory
Wheel Chair User
|
1 participants
n=99 Participants
|
|
Presence of Fecal Incontinence at Baseline
|
5 Participants
n=99 Participants
|
PRIMARY outcome
Timeframe: Data collection started following consent and procedural training and was collected daily from day 1 for the duration of the study, an average of 135 days.Population: The data from a total of 5 participants were analyzed for each arm of the study.
Fecal soiling was defined as non-toilet elimination, which was tracked and documented by the parent/child as direct event recording and tallied as the number of pairs of underwear/protective undergarments soiled with stool per day. The purpose of this outcome measure was to document the number of individuals who gained continence on NS and USP glycerin. Descriptive statistics was limited to percentage of total participants who achieved continence on each flushing regimen. Data was calculated on the last data point in the final phase for both the NS and USP glycerin flush.
Outcome measures
| Measure |
Subjects Continent on NS Antegrade Flush
n=5 Participants
Number of participants that gained and maintained continence on antegrade enema.
|
Subjects Continent on USP Glycerin
n=5 Participants
Number of participants that gained and maintained continence on USP Glycerin antegrade enema.
|
|---|---|---|
|
Fecal Soiling - Number of Participants That Gained and Maintained Continence on Each Flushing Regimen
|
1 Participants
|
4 Participants
|
PRIMARY outcome
Timeframe: Data collection began following consent and procedural training and was collected daily from day 1 for the duration of the study, an average of 135 days.Population: The data from a total of 5 participants were analyzed for each arm of the study.
Fecal soiling was defined as non-toilet elimination, which was tracked and documented by the parent/child as direct event recording and tallied as the number of pairs of underwear/protective undergarments soiled with stool per day. Descriptive statistics included mean and standard deviation. Inferential statistical analysis was accomplished using a two-tailed, two-sample pooled variance t test with a significance level set at 0.05, calculated on the data from the last day of the completed NS and USP Glycerin phases of the study. Power analysis conducted using data from this study with α = 0.5, power of .80, correlation between two means of .598, and effect size of 1.554 estimated a sample size of 11 would be needed to minimize the risk of a Type II error to (20%).
Outcome measures
| Measure |
Subjects Continent on NS Antegrade Flush
n=9 Fecal Soiling
Number of participants that gained and maintained continence on antegrade enema.
|
Subjects Continent on USP Glycerin
n=1 Fecal Soiling
Number of participants that gained and maintained continence on USP Glycerin antegrade enema.
|
|---|---|---|
|
Fecal Soiling - Quantitative Count Detailing the Number of Episodes of Fecal Incontinence Per Day on NS and USP Glycerin
|
2 underwear soiled/day
Standard Deviation 1.87
|
0.2 underwear soiled/day
Standard Deviation 0.45
|
SECONDARY outcome
Timeframe: Frequency of administration data was collected as the total number of flushes recieved over the last three days of each dosing phase for both NS and USP Glycerin and recorded as either daily (1), every other day (2), or every third dayPopulation: The data from a total of 5 participants were analyzed for each arm of the study.
Flush administration frequency necessary to achieve continence was recorded as a single measure per subject per flush solution obtained as the number of flushes in the last three days of each dosing phase and recorded as either daily (1), every other day (2), or every third day (3). The larger the value, the less frequent the flush, the better the clinical outcome. Dosing frequency was measured using direct observational recording completed by the parent or child. Descriptive analysis included mean, and standard deviation. Inferential statistical analysis was accomplished using a two-tailed, two-sample pooled variance t test with a significance level set at 0.05. Descriptive and inferential statistics were calculated on the data from the last day of the completed NS and USP Glycerin phases of the study.
Outcome measures
| Measure |
Subjects Continent on NS Antegrade Flush
n=5 Participants
Number of participants that gained and maintained continence on antegrade enema.
|
Subjects Continent on USP Glycerin
n=5 Participants
Number of participants that gained and maintained continence on USP Glycerin antegrade enema.
|
|---|---|---|
|
NS and USP Glycerin Flush Solution Dosing Frequency Necessary to Achieve Continence
|
1 Flush administration/day
Standard Deviation 0
|
1.6 Flush administration/day
Standard Deviation 0.894
|
SECONDARY outcome
Timeframe: Data for analysis was collected from the last flush of the NS and USP Glycerin dosing phase of the studyPopulation: Subjects limited to those who gained continence (2 saline, 4 USP Glycerin). One subject gained and maintained continence on saline in both the dosing and maintenance phases of the study and one subject who gained continence during the dosing phase of the study but failed to maintain continence on saline during the maintenance phase of the study.
Flush volume was measured in mL/flush using a graduated cylinder and recorded by the parent or child with each flush and later calculated in mL/kg. Data derived from the last flush of the completed dosing phase of both NS and USP Glycerin were used to calculate flush volume. Descriptive analysis included mean, median, range, and standard deviation. Reported data excludes subjects who failed to gain and maintain continence on either flushing regimen.
Outcome measures
| Measure |
Subjects Continent on NS Antegrade Flush
n=2 Participants
Number of participants that gained and maintained continence on antegrade enema.
|
Subjects Continent on USP Glycerin
n=4 Participants
Number of participants that gained and maintained continence on USP Glycerin antegrade enema.
|
|---|---|---|
|
Flush Volume
|
39.215 mL/flush
Standard Deviation 12.424
|
1.475 mL/flush
Standard Deviation 0.457
|
SECONDARY outcome
Timeframe: Collection dates included a baseline sample (week 1) and at the completion of the dosing trail for both NS and USP glycerin for a total of 3 samplesPopulation: The data from a total of 5 participants were analyzed for each arm of the study.
Evaluated impact of NS and USP Glycerin antegrade flush on serum electrolytes using a blood test called a Basic Metabolic Panel. Data analysis limited to percentage of subjects demonstrating any electrolyte abnormality on NS or USP glycerin.
Outcome measures
| Measure |
Subjects Continent on NS Antegrade Flush
n=5 Participants
Number of participants that gained and maintained continence on antegrade enema.
|
Subjects Continent on USP Glycerin
n=5 Participants
Number of participants that gained and maintained continence on USP Glycerin antegrade enema.
|
|---|---|---|
|
Number of Participants With Any Electrolyte Abnormality
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Collection dates included a baseline sample (week 1) and at the completion of the dosing trail for both NS and USP glycerin for a total of 3 samplesPopulation: The data from a total of 5 participants were analyzed for NS and 4 participants for USP Glycerin
Stool calprotectin was used to evaluate the impact of NS and USP Glycerin antegrade flush on colonic health. Calprotectin levels were obtained at baseline and following completion of the NS and USP Glycerin dosing phase of the study. Descriptive data analysis included mean and standard deviation for each flush regimen. Inferential statistical analysis was accomplished using a two-tailed, two-sample pooled variance t test with a significance level set at 0.05. Both descriptive and inferential data analysis was calculated on the difference in calprotectin levels between samples obtained at baseline and samples obtained following the completion of the NS and USP Glycerin flush (value at completion of dosing phase - baseline value). The assumption was the length of each dosing phase was sufficient to achieve a credible active washout period and therefore levels obtained at the end of a phase reflected flushing regimen effects colonic health regardless of flush order.
Outcome measures
| Measure |
Subjects Continent on NS Antegrade Flush
n=5 Participants
Number of participants that gained and maintained continence on antegrade enema.
|
Subjects Continent on USP Glycerin
n=4 Participants
Number of participants that gained and maintained continence on USP Glycerin antegrade enema.
|
|---|---|---|
|
Change in Stool Calprotectin Levels Assessed Through Comparing Levels Obtained Following Completion of NS and USP Glycerin Dosing Phases With the Baseline Value For Each Subject
|
133.7 μg/g
Standard Deviation 183.359
|
108 μg/g
Standard Deviation 113.874
|
SECONDARY outcome
Timeframe: Data analysis was completed on data obtained during the last flush in both the NS and USP Glycerin dosing phasePopulation: The data from a total of 5 participants were analyzed for each arm of the study.
Cramping with flush was measured using the Wong Baker Faces Pain Rating Scale (WBFPRS). The WBFPRS has undergone extensive testing and has well established psychometrics in the pediatric population. The scale ranges from 0 (very happy without pain) to 10 (the worse pain imaginable). Each pain level is associated with a facial expression. The child is asked to choose the face that best describes his/her level of discomfort (ordinal data). The parent was instructed to call if the child had flushing regimen-associated discomfort greater than a 4 on the WBFPRS. Documentation of pain severity was completed by the parent and child on a data-collection form at the time of occurrence. Descriptive statistics including mean and standard deviation. Inferential statistical analysis was accomplished using a two-tailed, two-sample pooled variance t test with a significance level set at 0.05. Descriptive and inferential statistics were calculated on the last data point in the dosing phase.
Outcome measures
| Measure |
Subjects Continent on NS Antegrade Flush
n=5 Participants
Number of participants that gained and maintained continence on antegrade enema.
|
Subjects Continent on USP Glycerin
n=5 Participants
Number of participants that gained and maintained continence on USP Glycerin antegrade enema.
|
|---|---|---|
|
Cramping With Flush
|
0 units on a scale
Standard Deviation 0
|
0.4 units on a scale
Standard Deviation 0.89
|
SECONDARY outcome
Timeframe: Data collection started with the first flush administered following discharge from the hospital and was collected with every subsequent flush through completion of the study, an average of 115 days.Population: The data from a total of 5 participants were analyzed for each arm of the study.
Vagal symptoms including nausea, vomiting, sweating, dizziness, and pallor were noted by the parent. The parent was instructed to call if the child had any vagal symptoms. Documentation of any vagal symptoms was completed by the parent and child on a data-collection form at the time of occurrence. Data was analyzed as a percentage of subjects experiencing vagal symptoms during flush with NS and USP glycerin.
Outcome measures
| Measure |
Subjects Continent on NS Antegrade Flush
n=5 Participants
Number of participants that gained and maintained continence on antegrade enema.
|
Subjects Continent on USP Glycerin
n=5 Participants
Number of participants that gained and maintained continence on USP Glycerin antegrade enema.
|
|---|---|---|
|
Number of Participants Experiencing Vagal Symptoms With Flush
|
0 Participants
|
1 Participants
|
Adverse Events
Vagal Symptoms With NS Flush
Vagal Symptoms With USP Glycerin Flush
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Vagal Symptoms With NS Flush
n=5 participants at risk
Number of subjects experiencing vasovagal symptoms (symptom complex including pallor, diaphoresis, dizziness, weakness, nausea, with or without syncope) with antegrade administration of NS flush solution
|
Vagal Symptoms With USP Glycerin Flush
n=5 participants at risk
Number of subjects experiencing vasovagal symptoms (symptom complex including pallor, diaphoresis, dizziness, weakness, nausea, with or without syncope) with antegrade administration of USP Glycerin flush solution
|
|---|---|---|
|
Vascular disorders
Vasovagal Response
|
0.00%
0/5 • 1 year 1 month
|
20.0%
1/5 • Number of events 1 • 1 year 1 month
|
Additional Information
Kimberly S. Jarczyk, PhD, C-PNP
Nemours Children's Clinic
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place